Literature DB >> 19906272

The utility of the Sysmex XE-2100 analyzer's NEUT-X and NEUT-Y parameters for detecting neutrophil dysplasia in myelodysplastic syndromes.

J R Furundarena1, M Araiz, M Uranga, M R Sainz, A Agirre, M Trassorras, N Uresandi, M C Montes, N Argoitia.   

Abstract

The diagnosis of myelodysplastic syndromes (MDS) is based on morphological changes in the blood and bone marrow. The parameters NEUT-X and NEUT-Y of the Sysmex XE-2100 analyzer could help detect neutrophil dysplasia. A control group of 50 patients, along with 50 postpartum patients, 50 anemias, 50 leukopenias, 50 patients with microscopically visible hypergranulated neutrophils and 50 MDS patients were assessed. The NEUT-X and NEUT-Y values (mean +/- SD) for the control group were 1346 +/- 28.2 and 420 +/- 19.3, respectively, with the anemia and leukopenia groups giving similar values. The postpartum and hypergranulated neutrophils groups presented higher values (P < 0.05), whereas the values in the MDS group were 1286 +/- 72.8 and 385 +/- 50.9 (P < 0.05), respectively. There were no differences between the morphological MDS types. The NEUT-X and NEUT-Y values in MDS patients with optical hypogranulation were significantly lower than for MDS patients without optical hypogranulation. NEUT-X and NEUT-Y values lower than 1298 and 398, respectively, would have a specificity for detecting MDS of 94% and 91% and would detect 60% and 56% of cases, respectively, whereas they would detect 75% and 74%, respectively, of MDS cases with optical hypogranulation. NEUT-X and NEUT-Y parameters can be used to detect neutrophil dysplasia arising from MDS and chronic myelomonocytic leukemia.

Entities:  

Mesh:

Year:  2009        PMID: 19906272     DOI: 10.1111/j.1751-553X.2009.01194.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  7 in total

1.  Technology and new fluorescence flow cytometry parameters in hematological analyzers.

Authors:  Borros M Arneth; Mario Menschikowki
Journal:  J Clin Lab Anal       Date:  2014-05-05       Impact factor: 2.352

2.  Clinical significance of cell population data (CPD) on Sysmex XN-9000 in septic patients with our without liver impairment.

Authors:  Sabrina Buoro; Michela Seghezzi; Mauro Vavassori; Paola Dominoni; Sara Apassiti Esposito; Barbara Manenti; Tommaso Mecca; Gianmariano Marchesi; Enrico Castellucci; Giovanna Azzarà; Cosimo Ottomano; Giuseppe Lippi
Journal:  Ann Transl Med       Date:  2016-11

3.  Leukocyte Cell Population Data Provide Clues for Myelodysplastic Syndrome in a 79-Year-old Male.

Authors:  Preethi S Chari; Sujay Prasad
Journal:  Indian J Hematol Blood Transfus       Date:  2017-03-14       Impact factor: 0.900

4.  A Preliminary Proposal for Quality Control Assessment and Harmonization of Leukocytes Morphology-structural Parameters (cell Population Data Parameters).

Authors:  Michela Seghezzi; Sabrina Buoro; Giulia Previtali; Valentina Moioli; Barbara Manenti; Ramon Simon-Lopez; Cosimo Ottomano; Giuseppe Lippi
Journal:  J Med Biochem       Date:  2018-12-01       Impact factor: 3.402

5.  Unique characteristics of leukocyte volume, conductivity and scatter in chronic myeloid leukemia.

Authors:  Balan Louis Gaspar; Prashant Sharma; Neelam Varma; Dmitry Sukhachev; Ishwar Bihana; Shano Naseem; Pankaj Malhotra; Subhash Varma
Journal:  Biomed J       Date:  2019-05-06       Impact factor: 4.910

Review 6.  Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes.

Authors:  Hussein Awada; Carmelo Gurnari; Arda Durmaz; Hassan Awada; Simona Pagliuca; Valeria Visconte
Journal:  Int J Mol Sci       Date:  2022-03-03       Impact factor: 5.923

7.  Beyond the In-Practice CBC: The Research CBC Parameters-Driven Machine Learning Predictive Modeling for Early Differentiation among Leukemias.

Authors:  Rana Zeeshan Haider; Ikram Uddin Ujjan; Najeed Ahmed Khan; Eloisa Urrechaga; Tahir Sultan Shamsi
Journal:  Diagnostics (Basel)       Date:  2022-01-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.